Amylin Agonists for Weight Loss: 2026 Pipeline, Trial Results, and FDA Status

What we actually verified

We think you should be able to see our homework. Here it is.

Checked and confirmed at the source on August 4, 2026:

• The FDA's current statement that cagrilintide cannot be used in compounding
• Pramlintide's initial U.S. approval, current labeled use, boxed warning, and the manufacturer's reported discontinuation of U.S. SymlinPen manufacture
• CagriSema's December 2025 FDA submission and Novo Nordisk's Q4 2026 decision guidance
• All four body-weight results from REDEFINE 1 under both the trial-product and treatment-policy estimands
• The REDEFINE 4 head-to-head result against tirzepatide, including the failed noninferiority endpoint
• Eloralintide's Phase 2 numbers and the current Phase 3 ENLIGHTEN program
• Petrelintide's Phase 2 result, including its stated efficacy estimand and candidate-specific tolerability findings
• ABBV-295's Phase 1 sample, duration, participant mix, and sponsor-reported topline results
• The active or filed development stage for every candidate in The RX Index Amylin Evidence Ledger
• Recruiting status and registry details for every trial in the current-trials table
• Ro's current membership pricing, Zepbound access language, free coverage checker, and prior-authorization support before including the one commercial CTA

What remains unknown, and is labeled unknown instead of guessed:

• Whether the FDA will approve CagriSema or what a final label would say
• A confirmed CagriSema launch date, retail price, savings program, or insurance coverage
• Which investigational candidate will ultimately offer the best balance of efficacy, tolerability, access, and long-term outcomes
• Whether amylin drugs preserve more skeletal muscle than GLP-1 drugs as a class
• The long-term safety profile and final contraindications of any investigational amylin candidate
• Whether an early-phase result will hold in a larger Phase 3 population

That last group is not a weakness. It's the difference between a page you can trust and a page that sounds confident.

Jump to what you need

• What amylin agonists actually are
• Are any FDA-approved?
• Every active human-stage program in our verified scope
• How much weight loss the trials reported
• Amylin vs. GLP-1
• Side effects
• The muscle question
• Can you buy it online?
• Trials enrolling now
• Trial and status checker
• When one could become available
• Wait, or discuss something approved now?
• FAQ

What are amylin agonists for weight loss?

Amylin is a hormone released with insulin in response to food. It helps regulate post-meal glucose, slows gastric emptying, suppresses inappropriate post-meal glucagon, and modulates satiety. Amylin agonists for weight loss are engineered drugs designed to mimic or activate that pathway for longer than natural amylin lasts.

Natural amylin is short-lived. The engineering challenge has been to create a molecule that can keep the useful signal going long enough to work as a practical medicine.

Most leading injectable candidates are being studied with once-weekly dosing. Specific programs are also exploring oral delivery or less-frequent injection schedules, but those schedules are investigational—not established prescription regimens.

How this is different from a GLP-1

Think of it this way.

GLP-1 drugs turn appetite down. Amylin drugs turn the feeling of fullness up.

That's a useful simplification, not a complete mechanism diagram. The two hormones act through different receptor systems, and both can influence appetite, satiety, gastric emptying, and post-meal physiology. That difference is exactly why drugmakers got excited: if two different biological signals can be used together, the combination may do more than either one alone.

That was the theory. We'll show you what actually happened when they tested it.

Not all “amylin drugs” are the same thing

This is where most coverage falls apart. Headlines lump several different designs into one bucket. They aren't the same, and the differences change what each study is actually testing.

Here's the plain-language breakdown we use throughout this page:

These categories can overlap: a sponsor may call a candidate an amylin analog while receptor studies also show calcitonin-receptor activity. We use the most decision-relevant verified description in the ledger.

A quick vocabulary note, since these terms show up everywhere and nobody defines them: “agonist” means a drug activates a receptor. “Analog” means an engineered molecule modeled on a natural hormone. “Investigational” means the drug is still being studied and is not available as a routine FDA-approved prescription for the use in question.

Why are so many people searching this right now?

Because three different things are pushing people here at once.

The first is news. Headlines keep calling amylin “the next Ozempic.”

The second is frustration. A lot of people typing this into a search bar are not curious bystanders. They're stuck.

The third is advertising. Peptide sellers are running hard at this keyword, and people want to know if what they're seeing is legitimate.

The search usually carries one of three questions underneath it: Could this help after my current medication stopped moving the scale? Could a different pathway be easier to tolerate? Is the cagrilintide being sold online legitimate?

Those are real decision frictions. They are not evidence that any candidate works, is safe, or is right for a particular person—and the page keeps them separate from the medical evidence.

Are any amylin agonists FDA-approved for weight loss?

No amylin-based medicine is FDA-approved specifically for chronic weight management in the United States as of August 4, 2026. Pramlintide is approved for a limited diabetes use, CagriSema has been submitted to the FDA for weight management, and every other current candidate on this page remains investigational.

Let's take those one at a time, because the details matter.

The one with an FDA approval—but not a weight-loss approval

Pramlintide is the original amylin drug. It showed that amylin signaling can be targeted in humans. It also shows why first-generation amylin treatment was burdensome.

Under its current label, Symlin is used with mealtime insulin in certain people with type 1 or type 2 diabetes who have not achieved desired glucose control despite optimal insulin therapy. It is injected before major meals. It carries a boxed warning—the FDA's most serious label warning—for severe hypoglycemia when used with insulin, particularly in people with type 1 diabetes. It was never approved for weight management.

Then, on October 27, 2025, AstraZeneca reported discontinuation of manufacture of both U.S. SymlinPen presentations.

That is not the same thing as the FDA withdrawing its approval. It also does not prove that every unit of residual inventory disappeared from every pharmacy on the announcement date. The accurate sentence is narrower: U.S. manufacture was discontinued, and no current amylin medicine is FDA-approved specifically for weight management.

Here's why we're spending a paragraph on a medicine that is no longer being manufactured for the U.S. market: many consumer articles still write “an amylin drug is already approved” without telling you the indication or the supply status. Technically incomplete. Practically misleading for someone searching for an available weight-loss medicine.

What CagriSema's FDA filing does and doesn't mean

Novo Nordisk submitted CagriSema to the FDA in December 2025. That's a real, dated, verifiable milestone. It is also only one of several gates between a clinical trial and an ordinary prescription.

Here's the full ladder between “filed” and “in your hands”:

1. Submission — completed in December 2025
2. FDA review — underway as of August 4, 2026
3. FDA action — Novo Nordisk says it expects a U.S. decision in Q4 2026; approval is not guaranteed
4. Final label — the approved indication, population, dosing, contraindications, and warnings
5. Manufacturer launch — approval and commercial launch are separate events
6. Distribution and pharmacy stock — product has to reach the supply chain
7. Price and savings terms — nothing final has been announced
8. Insurance and formulary coverage — payers make separate decisions

Anyone giving you a confident price, coverage policy, or pharmacy date today is skipping steps that have not happened.

For the blow-by-blow on CagriSema specifically, see our current CagriSema FDA and availability status page. This page covers the whole class.

So what does “investigational” actually get you?

Nothing you can buy as a routine FDA-approved prescription. That's the honest answer.

An investigational drug may be administered through a registered clinical study when a site is recruiting and the study team determines that someone qualifies. A trial existing is not proof that the drug will be approved, and a sponsor's development plan is not a launch promise.

### Nothing is approved for weight management. That doesn't mean you're stuck. CagriSema could reach an FDA decision in Q4 2026; every other current candidate is earlier. None has a guaranteed approval, launch date, price, or coverage policy. But the question underneath your search—what should I actually be doing about my weight right now—has options today, and the right one depends on your state, your insurance, your preferred form, and whether you want an FDA-approved or compounded treatment path. See the treatment paths that fit your situation → Free. About 60 seconds. Any compensated relationship is disclosed and does not change the matching criteria.

The right GLP-1 provider isn't the same for everyone—it depends on your state, your insurance and formulary, whether you want an FDA-approved or compounded medication, your preferred form (injection or oral), and your budget. Because a general answer can't resolve those for you, use The RX Index's Find My GLP-1 Path tool to get a personalized provider match with source-verified pricing before you choose.

Which amylin drugs are being studied for weight loss in 2026?

Our verified scope contains 14 active or filed human-stage amylin-containing candidates or fixed-combination programs as of August 4, 2026. They range from one FDA-submitted combination to Phase 3, Phase 2, and newly started Phase 1 programs. They are not equivalent: a completed pivotal program and a 12-week Phase 1 study are different kinds of evidence.

Before you look at the table below, we need to say something that works against us.

The honest problem with every amylin comparison—including ours

The biggest number in this table is not automatically the best drug.

These studies differ in phase, size, length, dose, population, comparator, and the statistical method used to calculate the result. We found no completed head-to-head human trial in the verified source set that directly compares two current amylin-only candidates.

So anyone publishing an “amylin leaderboard” is ranking things that were never raced.

If you came here for a simple winner, we don't have one, and we'd rather lose you than invent one. But that limitation is exactly why we built this the way we did. Instead of ranking, we put the study design beside every result—the phase, length, sample, comparator, estimand, current status, and legitimate-access answer—so you can see which numbers are actually comparable and which aren't.

The RX Index Amylin Evidence Ledger — August 2026

Scope: active or filed human-stage amylin-containing programs being developed for obesity or chronic weight management that we identified in current sponsor, registry, regulatory, and human-study sources. It is not a claim to include every preclinical molecule worldwide. Sorted by regulatory stage, then evidence maturity—never by the largest weight-loss percentage.

Candidate names link to the primary human-result, sponsor-pipeline, or trial-registry source used for that row. Every row was last checked August 4, 2026.

Count it up: 14 active or filed human-stage candidates or fixed-combination programs in this verified scope. Zero approved specifically for chronic weight management.

That single line is more useful than any unsupported ranking.

Reference and historical programs kept outside the active count

The candidates that matter most, explained

CagriSema—closest to the finish line, but it missed its head-to-head goal

CagriSema is one injection containing two separate drugs: cagrilintide, the amylin half, and semaglutide, the same molecule in Wegovy. It is not a single dual-action molecule, and that distinction matters when you read about zenagamtide later.

It's furthest along because it's the only amylin-containing weight-management product submitted to the FDA.

It also has a problem we'll cover in detail below: in February 2026, Novo ran it directly against tirzepatide—the drug in Zepbound—and CagriSema did not meet the trial's primary goal of demonstrating noninferiority. Tirzepatide produced the larger mean reduction in both reported estimands.

Cagrilintide—the amylin-only Phase 3 program

Cagrilintide is CagriSema without semaglutide. Novo is developing it on its own in the Phase 3 RENEW program.

That matters because it separates the amylin signal from the GLP-1 combination. It is also the molecule the FDA has singled out by name as prohibited from compounding under federal law. More on that below, because it's the most practically important thing on this page.

Zenagamtide, formerly amycretin—one molecule doing two jobs

You may know this one as amycretin. Novo renamed it zenagamtide.

It's genuinely different from CagriSema: instead of two drugs in one injection, it is a single engineered molecule that activates both GLP-1 and amylin receptors. Separate subcutaneous and oral weight-management programs have advanced into Phase 3 development.

Its early obesity numbers are the largest in this ledger—up to 24.3% over 36 weeks in the subcutaneous study. Hold that loosely. The study randomized 125 people and was designed for early safety, tolerability, pharmacokinetic, and dose-finding questions. Results can change materially in larger Phase 3 populations.

Eloralintide—the highest amylin-only mean result in this ledger, and the biggest open question

Lilly's eloralintide produced 9.5% to 20.1% average weight reduction across doses over 48 weeks, compared with 0.4% on placebo, under the efficacy estimand.

That top number is materially higher than cagrilintide's amylin-only result in REDEFINE 1.

We want to be careful here. Different trial, different people, different length, different dosing, different phase. But it's one of the most important unresolved questions in the class, and nobody yet knows whether eloralintide is a better-performing molecule or whether the difference will narrow when tested in a larger Phase 3 program.

Lilly's ENLIGHTEN program is now recruiting across multiple studies—including ENLIGHTEN-6 for people who still have obesity or overweight while taking a stable weekly incretin medicine.

Petrelintide—betting on tolerability instead of the biggest number

Petrelintide's 10.7% is smaller than the largest headline percentages in the leading programs. Zealand and Roche are not hiding from that. Their development case emphasizes tolerability, and the candidate-specific Phase 2 findings are unusual enough to be worth your attention.

Petrelintide does not currently have the largest reported trial percentage. If the only filter is the biggest early number, another candidate looks more impressive. The reason to follow petrelintide is whether its efficacy-tolerability balance survives larger trials.

ABBV-295—the early less-frequent-dosing experiment

ABBV-295 posted high-single-digit reductions in a 12- to 13-week Phase 1 study across weekly and less-frequent schedules.

That is encouraging as an early signal. It is also a short study of 76 people, 88.3% of whom were male, with a mean BMI below 30. Monthly dosing was tested only after an initial weekly period; it is not an established monthly regimen.

The earlier bench

MET-233i, AZD6234, KBP-336, Triple, Amylin 355, Amylin 1213, VRB-103, and BGM1812 are all real human-stage programs. None has a mature public weight-loss result in the verified source set that belongs beside a Phase 2 or Phase 3 percentage yet.

That absence is information. A registry entry proves a study exists. It does not prove efficacy.

Sponsor framing vs. what the source actually establishes

This is one of the page's original evidence checks: promotional framing on the left, decision-grade fact on the right.

How much weight loss do amylin agonists actually cause?

Selected amylin-containing trials have reported average weight reductions from high single digits to above 20%, but the values are not directly rankable. The cleanest amylin-only Phase 3 result is cagrilintide in REDEFINE 1: 11.5% average reduction under the treatment-policy estimand over 68 weeks, versus 3.0% with placebo.

This section is where the four-arm design lets us calculate something most coverage does not show.

The trial that separated amylin from GLP-1

REDEFINE 1 ran four groups at once for 68 weeks in 3,417 people:

Treatment-policy estimand, 68 weeks. Source: REDEFINE 1, New England Journal of Medicine.

Look at that third row again. 11.5%. That's cagrilintide on its own in a Phase 3 study.

It's a real, meaningful trial result. It's also roughly half the combination percentage people see in headlines.

What the four arms suggest about the combination

Now here's the calculation, and you can check every step.

If the placebo-adjusted mean effects were perfectly additive, the combination would equal semaglutide's 11.9-point effect plus cagrilintide's 8.5-point effect: 20.4 percentage points.

The observed placebo-adjusted combination effect was 17.4 points.

That's about 85% of the arithmetic sum of the two placebo-adjusted monotherapy effects.

Flip it around: CagriSema's mean body-weight reduction was 5.5 percentage points greater than semaglutide's in the treatment-policy results (20.4 minus 14.9). Cagrilintide's placebo-adjusted monotherapy effect was 8.5 points. The 5.5-point difference is about 65% of that 8.5-point monotherapy effect.

Still real. Still useful for understanding the study. Just not the same thing as adding two headline percentages together.

How we got this, and what it cannot tell you: This is descriptive arithmetic on published average results from four parallel arms of one randomized trial. It is not a formal interaction test. It does not account for confidence intervals. Most important, it does not estimate how much an individual already taking semaglutide would lose after adding cagrilintide; REDEFINE 1 randomized people to separate parallel groups and was not designed as an add-on study. A trial that directly adds amylin to stable incretin therapy answers that question better than this arithmetic.

Why the same drug has two different numbers

Here's a thing that trips up almost every article on this topic, and once you see it you'll spot it everywhere.

You'll read that CagriSema produced 22.7% weight loss. You'll also read 20.4%. Both are correct. Same trial, different estimands.

An estimand defines the treatment effect a trial is trying to estimate, including how the analysis handles treatment discontinuation, dose changes, and rescue treatment.

• Trial-product estimand: estimates what would happen if participants remained on assigned treatment, regardless of dose level, without rescue intervention
• Treatment-policy estimand: estimates outcomes regardless of whether participants discontinued treatment or used rescue intervention

Neither is dishonest. They answer different questions. But if a page quotes one drug's trial-product number beside another drug's treatment-policy number, the comparison is broken.

Here's the REDEFINE 1 decoder:

Notice something. The 2.3-point gap for CagriSema is nearly eight times the 0.3-point gap for cagrilintide.

We're not going to tell you why—this arithmetic does not establish a cause. But the observation is worth holding onto: CagriSema's reported mean was more sensitive to the estimand choice in this trial than cagrilintide's.

Eloralintide's 20.1% headline is also an efficacy-style estimand, so it should not be placed beside a treatment-policy figure without the label. Petrelintide's 10.7% was reported under an efficacy estimand. The study populations, phases, doses, and durations still differ.

If you take one skill away from this page, make it this one. It'll protect you from every trial-comparison headline in this category for the next few years.

How are amylin agonists different from GLP-1 drugs?

Amylin and GLP-1 are separate hormones that work through separate receptor systems, even though both can affect appetite, satiety, gastric emptying, and post-meal physiology. Some investigational drugs target amylin alone, some combine a separate amylin drug with a GLP-1 drug, and some build both activities into one engineered molecule.

The “fullness up, appetite down” line is a memory aid, not a claim that either pathway does only one thing. The current Symlin prescribing information describes pramlintide's effects on gastric emptying, post-meal glucagon, and satiety; approved GLP-1 labels describe their own broader pharmacology.

Is amylin “the next GLP-1”?

No, and the shorthand causes real confusion.

GLP-1-based medicines are already approved and prescribed for defined uses. The current amylin weight-management pipeline is a mix of one submitted product and investigational Phase 1, 2, and 3 programs.

Amylin may become an important companion to GLP-1 therapy, a separate treatment path, or both. It has not already replaced or surpassed the approved class.

Is CagriSema one drug or two?

Two active drug components delivered together: cagrilintide and semaglutide.

That distinction matters. CagriSema is a fixed-dose combination, not one molecule that activates both receptors. It also means that compounded semaglutide is not “compounded CagriSema”; it lacks the cagrilintide component, and the FDA says cagrilintide cannot be used in compounding.

Is zenagamtide the same as CagriSema?

No. CagriSema combines two molecules in one weekly injection. Zenagamtide is one engineered molecule with both GLP-1- and amylin-receptor activity, and separate oral and subcutaneous programs are in Phase 3 development.

Why would anyone want an amylin drug without a GLP-1?

Three real research questions keep pushing amylin-only programs forward.

Different tolerability. A cagrilintide study is recruiting people who previously stopped semaglutide or tirzepatide because of gastrointestinal intolerance. That trial exists because a different mechanism and titration approach may matter—not because the answer is already known.

Persistent obesity on an incretin. ENLIGHTEN-6 is studying eloralintide in people who still have obesity or overweight while receiving a stable weekly incretin medicine. It is designed to answer an add-on question that REDEFINE 1 could not.

Long-term treatment design. Researchers are also studying whether an amylin-focused medicine could offer a different efficacy-tolerability balance for chronic treatment. That remains a development goal, not a proven class advantage.

Fair warning: these are the reasons the trials are being run. No amylin medicine has yet earned an FDA-approved weight-management label for any of these situations.

What side effects have amylin trials actually found?

Gastrointestinal effects recur across amylin development, but their frequency varies sharply by candidate, dose, titration, and whether a GLP-1 drug is included. In REDEFINE 1, gastrointestinal adverse events were reported by 79.6% of the CagriSema group, 73.8% of the semaglutide group, 54.0% of the cagrilintide group, and 39.9% of the placebo group.

The entire pitch for amylin is “easier to tolerate.” The evidence does not support that as a class-wide conclusion.

What the evidence supports is narrower: some amylin-only candidates have produced encouraging tolerability findings in specific trials, while combining cagrilintide with semaglutide did not eliminate the gastrointestinal burden associated with treatment.

The cleanest same-trial safety comparison

Same 68-week Phase 3 trial. Source: REDEFINE 1, New England Journal of Medicine. These figures compare treatment groups inside one study; they should not be pasted beside percentages from unrelated trials as though the designs were identical.

Most gastrointestinal events in REDEFINE 1 were mild to moderate and occurred mainly while doses were being increased. That matters. It does not make several weeks of nausea or vomiting irrelevant to the person experiencing it.

Where petrelintide's tolerability story holds up

Petrelintide's Phase 2 ZUPREME-1 result is unusual enough to deserve exact numbers.

At the maximally effective dose, Roche reported:

• no vomiting
• no discontinuations because of gastrointestinal adverse events
• 4.8% treatment discontinuation because of any adverse event, versus 4.9% with placebo
• 98% of participants reaching the maintenance dose in the cohort with the greatest mean weight reduction

Across all petrelintide arms, trial withdrawal for any reason was 8.4%, versus 13.6% with placebo. Those are sponsor-reported Phase 2 findings from 493 participants—not a final label and not proof that petrelintide is safer than GLP-1 drugs. The Roche ZUPREME-1 release also says the most common adverse events were gastrointestinal and mostly mild.

Petrelintide's 10.7% result does not lead the efficacy table. If maximum early weight loss is your only filter, another candidate looks stronger. Its reason to remain interesting is whether this candidate-specific tolerability signal survives Phase 3.

What eloralintide's Phase 2 trial found

Lilly reported that the most common adverse events were mild-to-moderate gastrointestinal symptoms and fatigue. They occurred more often at higher doses, and slower dose escalation reduced their incidence. The two lower-dose groups had overall adverse-event rates similar to placebo in the sponsor's report tied to the 48-week publication.

That supports further study of dose and titration. It does not establish that eloralintide is easy to tolerate for every patient or that selective amylin agonism guarantees fewer gastrointestinal effects.

What Phase 1 and Phase 2 cannot tell you

Early trials are small or short because their first jobs are dose selection, pharmacology, and initial safety—not detecting every uncommon or long-term risk.

No investigational amylin candidate has a final FDA weight-management label listing its full indication, contraindications, warnings, drug interactions, and required monitoring. Those facts do not exist until regulatory review is complete.

Pramlintide's existing label carries a boxed warning for severe hypoglycemia when used with insulin and requires careful insulin adjustment and glucose monitoring. That warning belongs to pramlintide in its labeled insulin-treated diabetes use. It should not be copied onto every investigational amylin drug—but it should also stop anyone from pretending the pathway is automatically risk-free.

Do amylin agonists protect muscle better than GLP-1 drugs?

Human evidence does not establish that amylin agonists preserve more skeletal muscle than GLP-1 drugs as a class. REDEFINE 1 included a small DXA subgroup and a new trial is directly studying muscle biology, but neither provides a completed head-to-head class verdict.

This one deserves a straight answer because it is one of the most repeated unproven claims in the category.

Animal findings and biological theory are reasons to run human studies. They are not human findings.

What the existing CagriSema body-composition analysis shows

REDEFINE 1 included a DXA substudy in about 7.4% of the randomized population. The published paper reported the following mean absolute changes at week 68:

That is useful evidence, but it does not prove muscle protection.

“Lean soft tissue” is not the same thing as skeletal muscle. It includes water and other non-fat tissue. The subgroup was also a small fraction of the full trial, and the comparison above does not establish that CagriSema preserves more functional muscle than an active GLP-1 comparator.

The trial designed to answer more of the muscle question

Novo Nordisk is running RASMUS, ClinicalTrials.gov ID NCT07527195, a Phase 1 study comparing CagriSema, cagrilintide, semaglutide, and placebo on measures that include skeletal-muscle insulin sensitivity, body composition, and physical function.

The registry lists:

• 100 participants
• one site in Denmark
• study start on April 10, 2026
• estimated primary completion on April 28, 2028

So if someone tells you today that amylin protects muscle, the honest response is: a study intended to produce better human evidence is still underway.

RASMUS will add candidate-specific information. It will not, by itself, prove that every amylin drug protects muscle better than every GLP-1 drug.

For the human evidence already available across weight-loss medicines, see our verified human lean-mass findings by weight-loss drug.

Can you buy cagrilintide, CagriSema, or any amylin drug online?

No investigational amylin product on this page is available as a normal FDA-approved weight-management prescription in the United States. The FDA states that cagrilintide cannot be used in compounding under federal law, is not a component of an FDA-approved drug, and has not been found safe and effective for any condition.

This is the section that can save someone money, and possibly more than money.

What the FDA actually said

The FDA's current unapproved GLP-1 drugs page names cagrilintide directly. The agency states that federal law does not permit cagrilintide in compounding, that it is not a component of an FDA-approved drug, and that it has not been found safe and effective for any condition.

That is not a normal shortage-compounding question. There is no lawful compounded cagrilintide pathway under the agency's current position.

Is “compounded CagriSema” a real product?

Not as a lawful compounded copy of the submitted combination.

CagriSema contains cagrilintide and semaglutide. The FDA says cagrilintide cannot be used in compounding. A pharmacy offering compounded semaglutide is offering a different product containing only one side of that combination, and compounded semaglutide itself is not FDA-approved.

The tell that should end your shopping trip

If a retail website publishes a consumer titration schedule for cagrilintide, walk away.

There is no FDA-approved cagrilintide indication, dose, titration schedule, or prescribing information. Clinical-trial protocols are research instructions for screened participants under investigator oversight; they are not consumer dosing directions.

A “research use only” disclaimer beside human dosing advice does not turn an unapproved vial into a legitimate treatment.

What the FDA's adverse-event count does—and does not—show

As of May 31, 2026, the FDA said it had received 990 adverse-event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide.

“Associated with” matters. The FDA notes that the information can be incomplete, adverse events are underreported, and a report does not by itself prove that the product caused the event.

Those counts concern compounded versions of molecules that have FDA-approved reference products. They do not validate cagrilintide. The FDA has also described fraudulent labels, products naming pharmacies that did not make them, improper shipping temperatures, and products sold as “research use only” while being marketed for human use.

For dated enforcement actions and source links, see our compounded GLP-1 enforcement tracker.

Red flags on any site selling an investigational amylin product

• “Research use only” printed beside human dosing instructions
• no licensed prescriber involved
• no registered study or named investigator
• no prescription requirement
• claims that an online vial is “the same as” material used in a clinical trial
• a guaranteed weight-loss percentage
• crypto-only payment
• no accountable manufacturer, lot information, or regulated supply chain
• dosing advice coming from a seller, group chat, or influencer instead of a study team or licensed clinician

If you're here looking for a vendor

We'll be direct: this isn't the page, and we don't publish one. If that's what you came for, you should leave.

If what you actually want is a legitimate treatment path you can discuss now, keep reading. The trial table and wait-versus-act section are for you.

Which amylin clinical trials are recruiting now?

A registered clinical trial is the legitimate access path for an investigational amylin drug, but not every major program is accepting new participants. As of August 4, 2026, recruiting studies include Phase 3 eloralintide trials, a cagrilintide study for prior gastrointestinal intolerance to semaglutide or tirzepatide, a Phase 3 CagriSema dose study, and the smaller RASMUS muscle study in Denmark.

This is the only “yes” on a page full of “no.” So we made it as useful as we could.

Start here: what are you actually trying to do?

• I stopped semaglutide or tirzepatide because of stomach side effects → look at NCT07607587
• I still have obesity or overweight while taking a stable weekly incretin → look at ENLIGHTEN-6
• I want to find any amylin trial near me → use the checker below
• I want something approved that I can discuss now → skip to the wait-versus-act section
• I'm tracking the science → bookmark the evidence ledger; we verify it monthly

Recruiting or active studies verified August 4, 2026

Registry status can change between page updates. A study marked “recruiting” can still have no open site near you, and a listed site can close enrollment before the registry catches up.

ENLIGHTEN-6 is relevant—but do not call it a plateau cure

The study is for people with persistent obesity or overweight while receiving a stable weekly incretin medicine. That is close to the language many searchers use when they say they have “stalled,” but the registry's eligibility criteria—not the reader's label for the experience—control enrollment.

It is also a research study, not proof that adding eloralintide works. The trial exists to find out.

What participation actually involves

You may receive placebo or a comparator. Screening excludes many applicants. Visit schedules, tests, travel, and medication washout rules can be demanding.

The sponsor generally covers the investigational drug and research procedures specified by the protocol. Travel reimbursement, routine medical care, and other costs vary by study and site; ask before consenting.

The study team decides eligibility. Nothing on this page means you qualify.

Questions worth asking a coordinator:

• What is known from earlier human studies?
• What treatment, placebo, or comparator might I receive?
• What dose-escalation process does the protocol use?
• What symptoms require an immediate call or withdrawal?
• What happens to my current medications?
• Which visits and tests are required?
• Who pays for research procedures, routine care, and travel?
• What follow-up happens after treatment ends?

Amylin Trial & Status Checker

The Amylin Trial & Status Checker turns the evidence ledger and current ClinicalTrials.gov records into a source-linked starting point. Choose whether you want to track a drug, look for a study near you, or leave the investigational lane and explore an approved treatment path; the study team—not this tool—decides eligibility.

Start with one question

What are you trying to do?

• Track a specific amylin candidate
• Find a registered clinical trial
• Explore an approved treatment path available now
• Understand the pipeline without applying anywhere

What you get

Your result shows the candidate and its aliases, molecular category, development phase, FDA status, legal-access answer, current recruitment status, nearest registered locations, official study contacts, high-level registry criteria, source links, and the record's retrieval time.

Every result must say “Potential study match—not a determination that you qualify.” The checker does not diagnose, give dosing instructions, or replace a study coordinator or licensed clinician. Health answers should not be stored by default.

If the interactive checker does not load, use the current-trials table above and follow the official registry links.

### Check what's actually recruiting near you Recruiting status changes, and sites open and close. Use the checker to filter the current registry instead of relying on an old list. Open the Amylin Trial & Status Checker above. It shows official study records and contacts. The study team decides who qualifies.

When could an amylin weight-loss drug actually be available?

CagriSema has the nearest verified U.S. regulatory milestone because Novo Nordisk submitted it to the FDA in December 2025 and currently says it expects a decision in Q4 2026. That is company guidance—not an FDA-announced approval date, a launch promise, or proof that pharmacies will have it immediately if approved.

Why “approved” and “available” are not the same event

The FDA can approve a product without telling you when the manufacturer will launch it, whether every dose will be stocked, what the cash price will be, or whether your insurer will cover it.

The sequence is:

1. FDA action
2. final prescribing information
3. manufacturer launch decision
4. distribution and pharmacy stock
5. cash pricing and savings terms
6. payer formulary and prior-authorization decisions

Anyone giving a confident CagriSema pharmacy date or price today is skipping facts that have not been announced.

Why we will not give every candidate a launch year

A study can fail, miss its statistical goal, change dose, pause recruitment, uncover a safety problem, or produce a label narrower than expected. Manufacturing and payer decisions add separate uncertainty after approval.

We would rather tell you the next verified milestone than turn a sponsor's development plan into a promise.

Our update commitment: we recheck the full ledger monthly, CagriSema's FDA status weekly during Q4 2026, and every candidate when a trial result, phase change, regulatory action, licensing event, or discontinuation is announced.

Should you wait for an amylin drug or discuss something approved now?

Waiting for an investigational drug is not a treatment plan. If you need a treatment decision now, a clinician can assess approved options using your medical history, current medicines, insurance, and goals while you track the amylin pipeline separately.

Here's the fact that should weigh most heavily in this decision, and it's the one the hype coverage buries.

The head-to-head nobody should hide

In REDEFINE 4, Novo Nordisk compared CagriSema directly with tirzepatide 15 mg for 84 weeks in 809 adults with obesity.

CagriSema lost its noninferiority test.

That means the trial did not meet its primary goal of showing that CagriSema was not unacceptably worse than tirzepatide under the prespecified statistical margin. Tirzepatide also produced the larger mean body-weight reduction in both reported estimands.

Source: Novo Nordisk REDEFINE 4 filing with the SEC.

The trial was open-label, and one head-to-head study does not settle every future question about dosing, tolerability, subgroups, or long-term outcomes. But it settles this much: the most advanced amylin-containing program did not demonstrate noninferiority to tirzepatide in that study.

The medication that produced the larger mean reduction—tirzepatide—is already FDA-approved for chronic weight management as Zepbound.

If you're delaying a needed treatment discussion solely because you assume CagriSema has already proved better than approved options, REDEFINE 4 is the strongest reason to reconsider that assumption.

Four honest paths

Path 1 — You have a current weight-related medical concern and are not receiving treatment. Do not make an open-ended wait for an investigational drug your default. Ask a licensed clinician to assess approved treatment paths, contraindications, benefits, risks, and coverage in the context of your health.

Path 2 — You still have obesity or overweight while taking a weekly incretin. Do two separate things: review the current treatment with your prescriber, and check whether a registered study such as ENLIGHTEN-6 might be relevant. Do not assume either dose escalation, switching, or trial participation is right without clinical review.

Path 3 — You are tracking the science and do not need an immediate treatment decision. Waiting for better evidence is reasonable when it is an intentional information decision rather than a substitute for care. Follow the dated milestones instead of buying an unapproved product.

Path 4 — You found someone selling cagrilintide. Stop. The FDA has named the molecule directly. There is no lawful compounded cagrilintide pathway under the agency's current position, and a retail seller cannot prove its vial is equivalent to material used in a registered trial merely by saying so.

Choosing an approved path now does not mean missing out

Starting or changing a medication is a clinical decision, not a loyalty pledge to one drug class.

If an amylin product is later approved, you and your prescriber can evaluate it using the final label, actual price, insurance coverage, and the evidence available then. You do not need to keep your current health on pause to preserve that future option.

### If waiting does not fit your situation, here is the approved lane the head-to-head evidence points toward REDEFINE 4 did not prove that tirzepatide is right for you. It did show that tirzepatide produced the larger mean weight reduction and that CagriSema failed its noninferiority goal. Ro offers access to FDA-approved Zepbound® when prescribed after clinician review, plus a free insurance coverage checker for the Zepbound pen and an insurance concierge that submits prior-authorization paperwork. Ro Body membership is $39 for the first month, then $149 month-to-month or $74 per month with an annual plan paid upfront. Medication is billed separately. Check Zepbound coverage and Ro's current pricing → (affiliate link) Eligibility, prescribing, coverage, and out-of-pocket cost depend on your clinical evaluation and insurance or cash-pay choice. Zepbound has a boxed warning because tirzepatide caused thyroid C-cell tumors in rats; whether it causes them in humans is unknown. It is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2. Review the current prescribing information. Not sure whether FDA-approved brand-name treatment is the right lane? Find My GLP-1 Path sorts the treatment paths in about 60 seconds.

How we built and checked this page

We assembled this page from FDA and DailyMed records, ClinicalTrials.gov registrations, peer-reviewed human studies, scientific presentations, and dated sponsor records. Every candidate is described through the same evidence and access fields, and claims we could not verify were removed instead of being turned into confident-sounding copy.

Our source order

1. FDA actions, current prescribing information, and regulatory statements
2. ClinicalTrials.gov records and record histories
3. Peer-reviewed human studies
4. Scientific conference presentations
5. Dated sponsor pipeline documents and results releases
6. Reputable trade reporting for industry context only
7. Forums and Reddit for searcher language only—never for safety, efficacy, or regulatory claims

Drug names, reconciled

What the Amylin Evidence Ledger records

For each active or filed human-stage program, the production dataset should include:

1. candidate and previous name
2. sponsor
3. molecular design
4. selective, dual, multi-agonist, or fixed combination
5. form and dosing frequency studied
6. current U.S. development stage
7. trial ID
8. population and randomized sample
9. duration
10. reported mean body-weight change
11. comparator
12. estimand
13. evidence-source type
14. safety or evidence limitation
15. FDA chronic-weight-management status
16. legitimate access today
17. compounding status
18. next verified milestone
19. source
20. row-level last-checked date

The ledger is an evidence map, not an RX Index Score for experimental drugs. Giving an investigational molecule a consumer score could look like a medical recommendation and would hide the fact that Phase 1 and Phase 3 evidence are not equivalent.

Evidence-maturity labels

• current FDA-approved label for another use
• submitted to the FDA
• peer-reviewed Phase 3 result
• Phase 3 sponsor topline result
• peer-reviewed Phase 2 result
• Phase 2 sponsor topline result
• Phase 1 public result
• registry-only human study
• historical discontinued program

What we deliberately left out

Seller claims. Vendor certificates treated as clinical proof. Social-media dosing anecdotes. Animal results presented as human findings. Percentages we could not trace to a source. Predictions about approval, price, launch, or insurance. Class-wide “safer,” “better tolerated,” or “muscle-sparing” claims. And any ranking of drugs across trials that were never designed to be compared.

Who created it, how, and why

Who: Kaden, founder of The RX Index, using The RX Index editorial and source-verification process. No medical reviewer or credential is claimed.

How: We reconciled aliases, checked regulatory status, extracted trial design and outcome fields, compared sponsor statements with the underlying source, and retained a visible unknown whenever the evidence did not support a definitive claim.

Why: This page exists to separate four things that get blurred constantly: what is approved, what has been submitted, what remains in research, and what is being sold outside a lawful treatment pathway.

If we removed every link on this page, the evidence ledger, same-trial calculation, trial-status table, and access warning would still be here. That's the standard we're holding ourselves to.

Corrections: if you find an error, contact us and we will verify it, correct it, and record substantive changes below.

Frequently asked questions

These answers close the short follow-up questions most likely to send someone back to search. Each answer gives the decision fact first, then the condition or limitation that changes it.

What is amylin?

Amylin is a hormone released from pancreatic beta cells alongside insulin after food. It helps regulate satiety, gastric emptying, and post-meal glucagon. Natural amylin is short-lived, so drug developers engineer longer-acting analogs or receptor agonists.

Is amylin the same as GLP-1?

No. They are separate hormones acting through separate receptor systems. Both can influence appetite, satiety, gastric emptying, and glucose regulation, which is why researchers study them alone and together.

Are any amylin agonists FDA-approved for weight loss?

No. As of August 4, 2026, no amylin-based medicine is FDA-approved specifically for chronic weight management in the United States. CagriSema is under FDA review; the other leading candidates remain investigational.

Was pramlintide approved for weight loss?

No. Pramlintide, sold as Symlin, was approved in 2005 as an adjunct for certain people with type 1 or type 2 diabetes who use mealtime insulin. It was never approved for weight loss, and AstraZeneca reported discontinuation of U.S. SymlinPen manufacture in October 2025.

Is cagrilintide FDA-approved?

No. Cagrilintide is investigational. It is being studied alone in Phase 3 and is one component of CagriSema, but it has not been found safe and effective by the FDA for any condition.

Can cagrilintide be legally compounded?

No. The FDA states that cagrilintide cannot be used in compounding under federal law, is not a component of an FDA-approved drug, and has not been found safe and effective for any condition.

Is “compounded CagriSema” a real product?

Not as a lawful compounded version of CagriSema. The combination contains cagrilintide, which the FDA says cannot be used in compounding. Compounded semaglutide is a different, unapproved product containing only one side of the submitted combination.

How much weight loss have amylin drugs produced?

The answer depends on the candidate, phase, duration, dose, population, comparator, and estimand. Cagrilintide alone produced 11.5% mean reduction over 68 weeks under the treatment-policy estimand in REDEFINE 1; eloralintide reported up to 20.1% at 48 weeks under an efficacy estimand in Phase 2. Combination and multi-agonist studies have reported larger figures, but those are not amylin-only results.

Which amylin drug produced the most weight loss?

Zenagamtide and CagriSema have some of the largest reported mean percentages in selected studies, but calling either the “winner” is not scientifically defensible. The trials differ materially, and no head-to-head trial has compared the active amylin candidates with one another.

Do amylin drugs cause less nausea than Ozempic or Wegovy?

That is not established as a class claim. Petrelintide produced encouraging candidate-specific Phase 2 tolerability findings, while REDEFINE 1 reported gastrointestinal adverse events in 54.0% of the cagrilintide group, 73.8% of the semaglutide group, and 79.6% of the CagriSema group. Dose, titration, population, and molecular design matter.

Is amylin better than tirzepatide?

Not based on the only direct CagriSema comparison. In REDEFINE 4, CagriSema produced 23.0% mean reduction under the efficacy estimand versus 25.5% with tirzepatide 15 mg and failed the prespecified noninferiority test. That result concerns CagriSema, not every future amylin candidate.

Do amylin drugs protect muscle?

Not established. REDEFINE 1 contains useful body-composition data, and RASMUS is studying muscle outcomes more directly, but no completed human evidence proves a class-wide skeletal-muscle advantage over GLP-1 drugs.

Can I buy an amylin weight-loss drug online?

Not as a normal FDA-approved weight-management prescription. Products sold online as cagrilintide or another investigational amylin drug are outside ordinary approved prescribing, and the FDA specifically says cagrilintide cannot be used in compounding.

Is CagriSema one drug or two?

It is one fixed-dose combination product containing two drug components: cagrilintide and semaglutide. It is delivered as one investigational weekly injection but is not one dual-action molecule.

Are amycretin and zenagamtide the same drug?

Yes. Zenagamtide is the current name for Novo Nordisk's candidate formerly called amycretin. It is one molecule with GLP-1- and amylin-receptor activity, being developed in separate oral and subcutaneous programs.

Is eloralintide a GLP-1 drug?

No. Eloralintide is being developed as a selective amylin receptor agonist without a GLP-1 component. That is why its amylin-only Phase 2 result receives separate attention.

Can I take an amylin drug with my current GLP-1?

Not as an ordinary approved prescription. No amylin medicine has an FDA-approved weight-management label, and combining an investigational drug with a current medication belongs inside a registered protocol or future approved labeling—not self-directed use. ENLIGHTEN-6 is one study investigating eloralintide in people receiving a stable weekly incretin.

When will the first amylin weight-loss drug launch?

No confirmed launch date exists. Novo Nordisk guides to a Q4 2026 FDA decision on CagriSema, but an FDA action, manufacturer launch, pharmacy stock, price, and coverage are separate milestones.

Will insurance cover an amylin drug?

There is no approved amylin weight-management product with a final U.S. price or established formulary coverage. Trial-related costs vary by protocol and site; future commercial coverage cannot be known until after an approval and payer decisions.

How do I find a legitimate amylin clinical trial?

Use the Amylin Trial & Status Checker on this page or search ClinicalTrials.gov directly. Legitimate research has a registered study, named sponsor, named sites, formal informed consent, and screening by the study team—not a retail checkout page.

Does a “recruiting” trial mean I qualify?

No. Recruiting means a study is accepting or seeking participants somewhere. The study team must confirm that you meet every inclusion criterion, do not meet exclusion criteria, and can complete the protocol.

What happens when an amylin trial ends or treatment stops?

It depends on the protocol, and long-term post-treatment outcomes remain incomplete for most candidates. Ask the study team about follow-up, transition of care, access after the study, and what happens to weight and other outcomes after the investigational treatment ends.

Still not sure which GLP-1 program is right for you? Take our free 60-second matching quiz.

Find My GLP-1 Path →

Related guides

• Current CagriSema FDA and availability status
• Approved options while zenagamtide remains investigational
• Verified human lean-mass findings by weight-loss drug
• GLP-1 clinical trials tracker: the full pipeline across all mechanisms
• Compounded GLP-1 enforcement tracker
• How obesity drugs reach FDA approval

Sources

Regulatory and labeling

• U.S. Food and Drug Administration — FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, content current June 15, 2026
• DailyMed — SymlinPen (pramlintide acetate) prescribing information
• FDA Drug Shortages Database — SymlinPen manufacture-discontinuation records
• FDA — Compounding-policy clarification for GLP-1 drugs, April 1, 2026
• FDA — March 3, 2026 warning-letter announcement concerning compounded GLP-1 marketing

Peer-reviewed and scientific human evidence

• Garvey WT, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. REDEFINE 1.
• Davies MJ, et al. Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. New England Journal of Medicine. REDEFINE 2.
• Billings LK, et al. Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week Phase 2, multicentre, double-blind, randomised, placebo-controlled trial. The Lancet. 2025.
• Dahl K, et al. Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a Phase 1b/2a randomised controlled study. The Lancet. 2025.
• Novo Nordisk scientific material — zenagamtide oral and subcutaneous development
• Novo Nordisk scientific material — REDEFINE 1 body-composition analysis

Sponsor filings, results, and pipeline records

• Novo Nordisk — CagriSema FDA submission announcement, December 18, 2025
• Novo Nordisk Q1 2026 investor presentation — Q4 2026 CagriSema decision guidance and current obesity pipeline, May 6, 2026
• Novo Nordisk SEC filing — REDEFINE 4 headline results, February 23, 2026
• Novo Nordisk Annual Report 2025 — obesity pipeline and RENEW program
• Eli Lilly — eloralintide Phase 2 results, November 6, 2025
• Roche — ZUPREME-1 petrelintide Phase 2 results, March 5, 2026
• AbbVie — ABBV-295 Phase 1 topline results, March 9, 2026
• Pfizer Q1 2026 pipeline update — MET-233i
• Takeda and Amylin — davalintide development decision, 2010
• Verdiva Bio — VRB-103 Phase 1 initiation, July 30, 2026

Current trial registrations

• NCT07607587 — cagrilintide after semaglutide or tirzepatide gastrointestinal intolerance
• NCT07392190 — ENLIGHTEN-6
• NCT07321886 — ENLIGHTEN-1
• NCT07282600 — ENLIGHTEN-2
• NCT07369011 — ENLIGHTEN-3
• NCT07353931 — ENLIGHTEN-4
• NCT07564414 — CagriSema dose study
• NCT07527195 — RASMUS
• NCT07220642 — RENEW 1
• NCT07220759 — RENEW 2
• NCT06595238 — AZD6234 Phase 2b
• NCT06851858 — AZD6234 Phase 2
• NCT06833749 — KBP-336 Phase 2
• NCT07575932 — MET-233i / PF-08653945 Phase 2
• NCT07224399 — BGM1812 Phase 1

Zepbound labeling and Ro commercial facts used in the single affiliate block

• DailyMed — Zepbound (tirzepatide) current prescribing information
• Ro Body membership pricing — checked August 4, 2026
• Ro GLP-1 Insurance Coverage Checker — checked August 4, 2026
• Ro insurance concierge and prior-authorization support — checked August 4, 2026

Change log

August 4, 2026 — Version 1.0. Initial publication. The Amylin Evidence Ledger was built across 14 active or filed human-stage programs in a defined U.S.-relevant source scope. Original calculations were added using the four REDEFINE 1 treatment-policy arms, with an explicit warning that parallel-group arithmetic does not predict an individual's add-on response. Pramlintide's approval, labeled use, boxed warning, and U.S. manufacture-discontinuation status were separated instead of being collapsed into “withdrawn.”

Nothing on this page is medical advice. Investigational drugs are not FDA-approved for weight management and are not available through ordinary prescribing. Talk with a licensed clinician before starting, stopping, or changing any medication.